FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to a method for maintaining antibody stability in a preparation comprising storing the antibody preparation for six months or more at 5 °C or more. Antibody preparation comprises (i) about 0.1–100 mg/ml of a human antibody that specifically binds to a human nerve growth factor (hNGF); (ii) about 0.01–1.0 % polysorbate 20; (iii) about 1–20 % sucrose and (iv) about 1 mM to about 50 mM acetate.
EFFECT: invention provides a greater degree of antibody stability after storage for several months.
11 cl, 12 ex, 38 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| STABILIZED PREPARATIONS CONTAINING ANTIBODIES AGAINST NGF | 2019 |
|
RU2728575C1 |
| STABILISED COMPOISITONS, CONTAINING ANTIBODIES TO INTERLEUKINE 6 (IL-6R) RECEPTOR | 2011 |
|
RU2554779C2 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
| LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
| ANTIBODY FORMULATIONS | 2017 |
|
RU2769326C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES TO C5 | 2018 |
|
RU2787595C2 |
| VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL INJECTIONS | 2007 |
|
RU2432155C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| STABLE FORMULATION ON THE BASIS OF ANTIBODY TO IFNAR1 | 2016 |
|
RU2731737C2 |
